Spoken Alpha
BeOne Medicines Ltd.
BeOne Medicines designs and develops oncology treatments across hematology and solid tumors, with approved medicines including BRUKINSA (a BTK inhibitor for blood cancers) and TEVIMBRA (a PD-1 inhibitor for various solid tumors).
BeOne Medicines Ltd is a Healthcare company operating in Biotechnology with a $32.27B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 4, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add BEIGF, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BEIGF.
$ curl https://api.spokenalpha.com/v1/companies/BEIGFFAQ
Spoken Alpha indexes BEIGF's earnings call transcripts at https://spokenalpha.com/companies/BEIGF. Each call links to attributed speakers and parsed analyst Q&A. BeOne Medicines Ltd.'s own investor relations page is at https://ir.beonemedicines.com/.
BeOne Medicines Ltd. (BEIGF) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-04 | $0.16 | — | — | $1.71B | — | — | EODHD |
| Q1 FY2026 | 2026-05-05 | $0.15 | — | — | $1.51B | — | — | EODHD |
| Q4 FY2025 | 2026-02-25 | $0.04 | — | — | $1.50B | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $0.08 | — | — | $1.41B | — | — | EODHD |
| Q2 FY2025 | 2025-08-05 | $0.06 | — | — | $1.32B | — | — | EODHD |
| Q1 FY2025 | 2025-05-05 | $0.00 | — | — | $1.12B | — | — | EODHD |
| Q4 FY2024 | 2025-02-23 | $-0.11 | — | — | $1.13B | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.09 | — | — | $1.00B | — | — | EODHD |
| Q2 FY2024 | 2024-08-06 | $-0.09 | — | — | $929.2M | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $-0.19 | — | — | $751.7M | — | — | EODHD |
| Q4 FY2023 | 2024-02-25 | $-0.27 | — | — | $634.4M | — | — | EODHD |
| Q3 FY2023 | 2023-09-29 | $0.15 | — | — | $781.3M | — | — | EODHD |
| Q2 FY2023 | 2023-06-29 | $-0.28 | — | — | $595.3M | — | — | EODHD |
| Q1 FY2023 | 2023-03-30 | $-0.26 | — | — | $447.8M | — | — | EODHD |
| Q4 FY2022 | 2023-02-26 | $-0.33 | $-0.57 | +42.1% | — | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-0.33 | $-1.68 | +80.4% | $306.6M | — | — | EODHD |
| Q2 FY2021 | 2021-08-04 | $-0.40 | — | — | — | — | — | EODHD |
| Q1 FY2021 | 2021-05-05 | $0.05 | — | — | — | — | — | EODHD |
| Q3 FY2020 | 2020-11-04 | $-0.37 | $-4.06 | +90.9% | — | — | — | EODHD |
| Q2 FY2020 | 2020-08-05 | $-0.33 | — | — | — | — | — | EODHD |
Source: EODHD. BEIGF reported actuals as published; sparse fields render as —.